More importantly, patients with high PD-L1 expression in the combination group had an ORR of 66% compared with 24% of the atezolizumab group.199 The phase III trial (SKYSCRAPER-01) is currently investigating tiragolumab plus atezolizumab in patients with newly diagnosed NSCLC and PD-L1 expression of at least 50%. This evidence concerns the gene CD274 and non-small cell lung carcinoma.